Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

In the latest close session, Gilead Sciences (GILD) was down 3.72% at $129.83. The stock's performance was behind the S&P 500 ...

With a short percentage of shares outstanding of 2.07%, Gilead Sciences, Inc. (NASDAQ:GILD) is among the 7 Best Longevity and Anti-Aging Stocks to Buy. On June 15, Gilead Sciences, Inc. (NASDAQ:GILD) ...

GILD recently won FDA approval for the label expansion of breast cancer drug Trodelvy (sacituzumab govitecan-hziy) for the ...

Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...

Check out the latest Gilead Sciences Inc. (GILD) stock quote and chart. View real-time stock prices & the company’s financial overview to help with your trading & investment.

Since December 2025, Gilead Sciences has been in a holding pattern, posting a small return of 2.7% while floating around $124.73. The stock also fell short of the S&P 500’s 10.9% gain during that ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the May 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GILD ...

Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Amgen (AMGN). But which of these two companies is the best ...